智通财经APP讯,中源协和(600645.SH)发布公告,公司全资子公司武汉光谷中源药业有限公司于2025年6月23日取得国家药品监督管理局药品审评中心(CDE)签发的关于VUM02注射液临床试验申请《受理通知书》,受理号为CXSL2500507。
VUM02注射液(人脐带源间充质基质细胞注射液)是我司自主研发的冷冻保存型细胞制剂,是由经筛选的健康新生儿脐带组织通过体外分离、扩增、收获、冻存后制备的人脐带源间充质基质细胞(UC-MSC)新药,临床拟用适应症增加重型/危重型肺炎的治疗。截至公告日,全球尚未有用于治疗重型/危重型肺炎的同类细胞药物上市,研发进展最快的同类药物处于临床试验阶段。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.